Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis Research

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2012.12.006PMID 23276528PMCID PMC3594437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins, inflammation and deep vein thrombosis: a systematic review

  2012cited by this paper
• Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.

  2012influential reference
• Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.

  2012cited by this paper
• Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous Thrombosis

  2011cited by this paper
• IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.

  2011cited by this paper
• Interleukin-6: a potential target for post-thrombotic syndrome.

  2011influential reference
• Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis

  2011cited by this paper
• Regulation of the endothelial plasminogen activator system by fluvastatin

  2010cited by this paper
• Statins suppress interleukin‐6‐induced monocyte chemo‐attractant protein‐1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells

  2010cited by this paper
• Thrombogenesis with continuous blood flow in the inferior vena cava

  2010cited by this paper
• Effects of race and ethnicity on the incidence of venous thromboembolism.

  2009cited by this paper
• A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

  2009influential reference
• The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

  2008cited by this paper
• The epidemiology of venous thromboembolism in the community.

  2008cited by this paper
• The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes.

  2008cited by this paper
• Incidence and mortality of venous thrombosis: a population‐based study

  2007cited by this paper
• Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.

  2007cited by this paper
• Mouse models for atherosclerosis and pharmaceutical modifiers.

  2007cited by this paper
• Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance.

  2007cited by this paper
• Statins, cardiovascular disease, and drug safety.

  2006cited by this paper
• Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism

  2006cited by this paper
• Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma.

  2006cited by this paper
• Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005cited by this paper
• Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins

  2005cited by this paper
• Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

  2005cited by this paper
• Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms

  2005cited by this paper
• Interleukin-6 and Mevastatin Regulate Plasminogen Activator Inhibitor-1 Through CCAAT/Enhancer-Binding Protein-&dgr;

  2005cited by this paper
• Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?

  2004cited by this paper
• D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis

  2004cited by this paper
• Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver.

  2004cited by this paper
• Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives.

  2003cited by this paper
• Safety and statin therapy: reconsidering the risks and benefits.

  2003cited by this paper
• Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB.

  2002cited by this paper
• Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients

  2002cited by this paper
• Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering

  2002cited by this paper
• Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells

  2002cited by this paper
• Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis.

  2002cited by this paper
• Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆

  2001cited by this paper
• Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

  2001cited by this paper
• The role of STATs in transcriptional control and their impact on cellular function

  2000cited by this paper
• Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.

  2000cited by this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998cited by this paper
• Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

  1998cited by this paper
• Venous endothelial damage produced by massive sticking and emigration of leukocytes.

  1974cited by this paper

• Association between serum triglyceride levels and venous thrombosis risk in older Chinese patients with fractures: a retrospective cross-sectional study

  2025cites this paper
• The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies.

  2025cites this paper
• Bioprinted Micro‐Clots for Kinetic Analysis of Endothelial Cell‐Mediated Fibrinolysis

  2025cites this paper
• Mice with reduced protease-activated receptor 4 reactivity show decreased venous thrombosis and platelet procoagulant activity

  2025cites this paper
• Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism

  2025cites this paper
• Acute Pulmonary Embolism and Immunity in Animal Models

  2024cites this paper
• Mice with Reduced PAR4 Reactivity show Decreased Venous Thrombosis and Platelet Procoagulant Activity

  2024cites this paper
• Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review

  2024cites this paper
• Immune cell–mediated venous thrombus resolution

  2023cites this paper
• Verständnis, Prävention und Behandlung von venösen und lymphatischen Erkrankungen basieren auf der Arbeit von Grundlagenforschern

  2022cites this paper
• Selection and in vitro and in vivo characterization of a Kunitz Protease Inhibitor domain of protease nexin 2 variant that inhibits factor XIa without inhibiting plasmin.

  2021cites this paper
• Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis.

  2021cites this paper
• Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging Predicts Vein Wall Scarring and Statin Benefit in Murine Venous Thrombosis

  2021cites this paper
• Extracellular DNA—A Danger Signal Triggering Immunothrombosis

  2020cites this paper
• Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms

  2020cites this paper
• The role of platelets in thrombus fibrosis and vessel wall remodeling after venous thrombosis

  2020cites this paper
• By word of mouse: using animal models in venous thrombosis research

  2020cites this paper
• Insights from experimental post-thrombotic syndrome and potential for novel therapies.

  2020cites this paper
• siRNA‐mediated silencing of PAI‐1 gene acts as a promoter over the recanalization of endothelial progenitor cells in rats with venous thrombosis

  2019cites this paper
• Resolvin D4 attenuates the severity of pathological thrombosis in mice.

  2019cites this paper
• Collateral vein dynamics in mouse models of venous thrombosis: Pathways consistent with humans.

  2019cites this paper
• Choosing a Mouse Model of Venous Thrombosis.

  2019cites this paper
• Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application

  2019cites this paper
• Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review

  2019cites this paper
• Effect of simvastatin on the SIRT2/NF-κB pathway in rats with acute pulmonary embolism

  2018cites this paper
• Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway

  2018cites this paper
• Update on the electrolytic IVC model for pre‐clinical studies of venous thrombosis

  2018cites this paper
• Gypenosides Altered Hepatic Bile Acids Homeostasis in Mice Treated with High Fat Diet

  2018cites this paper
• Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Hα1 in ApoE-/- mice.

  2018cites this paper
• Statins as a preventative therapy for venous thromboembolism.

  2017cites this paper
• Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering

  2017cites this paper
• Statins in venous thrombosis: more evidence, more basic science findings

  2017cites this paper
• Simvastatin ameliorates deep vein thrombosis in rabbits by regulating the fibrinolytic system

  2016cites this paper
• VEGFR2 Gene Polymorphism Correlates with Deep Venous Thrombosis Risk in Chinese Han Population

  2015cites this paper
• Inflammation in venous thromboembolism: Cause or consequence?

  2015cites this paper
• The role of galectin-3 and galectin-3-binding protein in venous thrombosis.

  2015cites this paper
• Venous thrombosis

  2015cites this paper
• Inferior vena cava branch variations in C57BL/6 mice have an impact on thrombus size in an IVC ligation (stasis) model

  2015cites this paper
• TGF-β1 and Serpine 1 expression changes in traumatic deep vein thrombosis.

  2015cites this paper
• Statins Improve the Resolution of Established Murine Venous Thrombosis: Reductions in Thrombus Burden and Vein Wall Scarring

  2015cites this paper
• Combined treatment with bexarotene and rosuvastatin reduces angiotensin‐II‐induced abdominal aortic aneurysm in apoE−/− mice and angiogenesis

  2015influential citation
• Detection of targets and their mechanisms for early diagnosis of traumatic deep vein thrombosis.

  2015cites this paper
• Effects of Rosuvastatin on Fibrinolytic System of Human Umbilical Vein Endothelial Cells In Vitro

  2014cites this paper
• Statins, aspirin and risk of venous thromboembolic events in breast cancer patients

  2014cites this paper
• Hyperlipidemia, tissue factor, coagulation, and simvastatin.

  2014cites this paper
• Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.

  2014cites this paper
• Impact of rosuvastatin treatment on reduction of thrombus burden in rat acute inferior vena cava stenosis

  2014cites this paper
• Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner.

  2014cites this paper
• The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse

  2013cites this paper
• Novel mediators and biomarkers of thrombosis

  2013cites this paper
• Inflammation, Thrombogenesis, Fibrinolysis, and Vein Wall Remodeling After Deep Venous Thrombosis

  2013cites this paper